Answers are grounded in this paper and cite their sources.
SEPTEMBER 2024 EDITORIAL BOARD FOCUS ON CLINICAL TRIALS—By AKSHAY SOOD AND ERIC SINGER Embracing Diversity in Clinical Trial Reporting In the rapidly evolving field of urologic oncology, the complexity of cancer challenges clinicians to tailor treatment strategies that meet the unique needs of each patient. A data-driven approach is essential to ensure the most effective treatments are applied, making clinical trials the cornerstone of evidence-based medicine. These trials not only validate the efficacy and safety of new therapies but also help refine existing treatments to enhance patient outcomes. The Journal is committed to advancing the understanding and management of urological conditions by publishing a wide variety of clinical trial subtypes. Recognizing the full spectrum, from protocols for active studies to under-accrued trials and from secondary endpoint evaluations to comprehensive registry trials, enriches the discourse within the medical community. This editorial aims to highlight the importance of this diversity and the value of preliminary trial reports in driving the field forward. The Importance of Varied Clinical Trial Reports 1. Negative trials: Often undervalued, trials that do not demonstrate a statistically significant effect are sometimes perceived as less publishable. However, these studies are invaluable, providing a check against the “positive publication bias” and offering a more complete picture of the research landscape. Publishing these trials helps delineate boundaries of efficacy and can guide future research directions, preventing unnecessary duplication of efforts and fostering more innovative approaches. A few notable examples include trials in advanced prostate,1–3 kidney,4,5,6,7,8,9,10 and bladder cancer,11,12 and more “simpler” surgical trials in localized bladder13,14 and prostate cancer.15–17 2. Protocols for active studies: Sharing protocols for ongoing trials fosters a culture of transparency and collaboration. Early dissemination of trial designs allows for peer input, potentially enhancing study methodologies and improving patient outcomes. It also serves to inform the community about current research efforts, avoiding overlap and fostering potential collaborations that could lead to multicenter trials. 3. Under accrued trials: Discussing trials that face enrollment challenges can spur community-wide reflection on the barriers to patient accrual and retention. Such discussions are crucial for developing more effective strategies to boost participation and for adjusting trial designs to be more inclusive and appealing to potential subjects (such as Zelen designs). A classic example of such a trial effort is that of comparative-effectiveness research between radical cystectomy and trimodality therapy in bladder cancer.18 Current trials of focal therapy in prostate cancer similar challenges.19 However, as noted above, it is important to report these failed accrual efforts because that may lead to better future trial designs, less restrictive patient participation criteria, or simply, avoid duplication of efforts elsewhere saving precious research dollars. 4. Secondary endpoints and subgroup analyses: While primary outcomes provide direct answers to research questions, secondary endpoints and subgroup analyses often yield insights that are equally valuable. Publications focusing on these can uncover additional benefits or risks associated with treatments, influencing clinical practice and guiding future research priorities. While these should be interpreted and reported with caution,220 when reported appropriately can lead to practice change and/or future trials. 5. Registry trials: Registry trials, with their rich real-world data, are crucial for understanding long-term outcomes and the broader implications of medical interventions.221 By leveraging existing registries and innovative trial designs (such as step-wedge design), these trials can be conducted at a reduced cost, with a minimal need for involvement of the Clinical Trials Office staff. This approach also lessens the burden of additional follow-ups on patients, thereby streamlining the trial process. In the rapidly evolving field of urology, registry trials are invaluable for continuously measuring the comparative-effectiveness of various interventions. They offer a dynamic platform to track and compare the outcomes of different treatments over extended periods, facilitating ongoing improvements in clinical practice. Furthermore, the integration of novel data systems with advancements in artificial intelligence in medicine is revolutionizing how data are captured and analyzed.222 These technological advancements will enable registry trials to handle vast amounts of data more efficiently, allowing for more sophisticated, granular, and timely analysis. The Role of Preliminary Reports Preliminary reports, often undervalued in the hierarchy of scientific communication, are crucial in the fast-paced realm of clinical research. They provide early insights into trends, feasibility, safety, and interim outcomes of ongoing trials. Early findings can attract attention from the broader medical community, potentially drawing in additional funding, especially critical for trials at risk of underfunding despite promising preliminary results. Such early-stage dissemination can also lead to early adoption of beneficial practices or swift cessation of harmful ones, significantly affecting patient safety and care. Funding and Open Access A significant challenge in conducting and publishing clinical trials is meeting funding requirements that often mandate open access publication. The costs associated with making articles freely available can be substantial, potentially limiting the dissemination of crucial research. Recognizing this barrier, the Journal is dedicated to facilitating the broad dissemination of clinical research findings. We are committed to supporting the publication of comprehensive primary trials that are required to be open access due to funding stipulations. By doing so, we ensure that critical data reach all researchers, clinicians, and patients globally, thereby democratizing access to information and advancing global health outcomes. Conclusions The broad spectrum of clinical trial subtypes and the strategic publication of preliminary reports are pivotal in enriching the scientific tapestry of urology. Each type of trial and report contributes uniquely to the collective knowledge base, challenging existing paradigms, confirming others, and continually refining our approach to patient care. In this spirit, the JUOP invites researchers to consider the diverse options for submission. SEPTEMBER 2024 JUOP NEW ARTICLES This month we have a dynamic group of 7 new articles in the methodology categories of health services research, qualitative study, retrospective/prospective mixed methods, and rare conditions. Many articles have related editorial comments from the peer reviewers for more in depth comments. To start, please read the special editorial from Soogoor et al23 who give a timely update on what urologists need to know about osteopathic medical school applicants to urology residents. As roughly 25% of medical students are in osteopathic medical students, and residency programs are now combined, the authors review some of the key metrics associated with their applications including the Comlex examination, the osteopathic medical school honors society Sigma Sigma Phi, and the types of letter of recommendation DO students often use from their rotation opportunities. At our center, we have had several outstanding residents and fellows from DO programs, and many of the applicants have demonstrated significant determination and creativity to prepare themselves for the urology match from DO programs that do not have home urology departments to support them. HEALTH SERVICES RESEARCH Golzy et al24 performed a valuable concept study on the relationship between the aging process and bladder cancer patients—given the older range of associated patients with the disease. They used the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey database which contained baseline and 2-year follow-up quality of life surveys (over 5000 survey sample size). They used machine learning and clustering techniques to classify older patients by quality of life (QOL) metrics (including activities of daily living). Age and socioeconomic status were significant predictors of which cluster of function patients were assigned. A key question was whether treatment categories affected cluster shifts over time, but the results showed fairly stable results between treatment groups—despite radical cystectomy being such a higher morbidity treatment than the alternatives. The lower functioning clusters also correlated with poorer overall survival. Tran et al25 performed a survey of prostate cancer impact in an Asian population. They used a quantitative survey method with patient and caregiver pairs and a qualitative interview structure. The areas of emphasis were anxiety and fear of cancer recurrence. The study also explores concerns and anxiety over treatment delays and concerns with knowledge about treatment options. A high proportion of patients present to urologists without symptoms, however have a high degree of concerns about treatment options, side effects, and future problems. One of my colleagues cleverly observed this discrepancy as the “Uro-Psychology” challenge with counselling and treating prostate cancer patients. RETROSPECTIVE STUDY Wang et al26 performed a retrospective deep dive into renal cell carcinoma imaging with the sestamibi scan to try and differentiate renal cell carcinoma from the more benign variants of oncocytoma. The key metrics were quantifying the target hot vs cold ratios. They found that altering the target-to-background ratios did not lead to a meaningful improvement in accuracy over a qualitative read. Therefore, an experienced radiologist may be the determining factor in meaningful staging information. Chung et al27 looked at the evaluations of muscle-invasive patients with bladder cancer completing neoadjuvant chemotherapy, as further classified by their clinical response. Using a prospective database, they assessed responses as complete or not and focused on the outcomes of patients later known to be misclassified. The rate of misclassified complete response was 11%, and they underwent delayed radical cystectomy after initial surveillance at a mean interval of 4.3 months. This resulted in a roughly 15% decrease in survival metrics compared with correctly classified patients. This is a small, single institution study with limitations but is an interesting concept worth additional study. Kong et al28 looked at the relationship between neurologic quality of life and lower urinary tract symptoms in patients with multiple sclerosis. From outpatient clinic encounters, they prospectively surveyed eligible patients with the NeuroQOL Short From and portions of the Bladder Control Scale of the Multiple Sclerosis Quality-of-Life Inventory. They added retrospective chart review. A significant association was between urgency, frequency, and urinary incontinence and the overall MS QOL score. Overall, 93% of patients had at least 1 lower urinary tract symptom. RARE CONDITIONS We have 2 rare conditions worth adding to your knowledge base. Ninomiya et al29 looked at a case of hyperthermic intraperitoneal chemotherapy resulting in scrotal ulceration that led to surgical excision to alleviate pain. Overall incidence estimated at 1.5% and the etiology may relate to a patent processes vaginalis allowing drug contact with the scrotum. Kirisawa et al30 looked at a series of 51 patients with urachal carcinoma with treatment outcomes. They correlated tumor involvement in perivesical fat and grade as prognostic for survival and explore adjuvant treatment options. PEOPLE, PLACES, AND THINGS For our pictorial series on academic urology culture, Drs Singer and Hasanov recap some highlights from the sixth Kidney Cancer Research Symposium. The sixth Annual Kidney Cancer Research Symposium (KCRS) was hosted by KidneyCAN (https://kidneycan.org/) from July 11 to 12, 2024, in Boston, MA. Per KidneyCan, “KCRS is an annual meeting of clinicians, researchers, research advocates, scientists, medical oncologists, industry and others to discuss the future efforts for collaboration in the field of kidney cancer research.” The program features presentations on projects that received award funding from the Department of Defense’s Kidney Cancer Research Program. This year’s meeting was led by Committee Co-Chairs Toni Choueiri, MD of the Dana-Farber Cancer Institute and Hans Hammers, MD, PhD of UT Southwestern Medical Center (Figure 1).Figure 1.: Drs Choueiri and Hammers.KCRS 2024 began with a gathering of more than 3 dozen clinical trialists invited from North America and Europe to explore the formation of a Renal Cell Carcinoma Perioperative Trial Collaborative (RCCPTC). This session was moderated by Drs Axel Bex from the Royal Free London Hospital and Grant Stewart from the University of Cambridge. The group is using a modified Delphi approach to generate a consensus statement on the future of perioperative systemic therapy trials in RCC (Figure 2).Figure 2.: Drs Axel Bex, Michael Jewett, and Grant Stewart during the RCCPTC meeting. RCCPTC, Renal Cell Carcinoma Perioperative Trial Collaborative.Dr Charles Swanton, from the Francis Crick Institute provided the keynote presentation titled “How the Air We Breathe Can Impact Cancer.” His thought-provoking lecture characterized poor air quality as a chronic inflammatory mediator of multiple diseases leading to early mortality; in the case of lung cancer, air pollution acts on macrophages to induce latent tumor progenitors (Figure 3).Figure 3.: Illustrated talk methodology: Relationships between the air we breathe and cancer.Dr Jeff Rathmell of Vanderbilt University Medical Center was another featured speaker and discussed “Obesity and Immunotherapy,” focusing on the obesity paradox wherein RCC incidence is higher in obese individuals, but their disease responds better to regimens containing anti–PD-1 immunotherapy (Figure 4).Figure 4.: Illustrated talk methodology: Obesity and Immunotherapy.The main sessions at the conference featured short oral presentations on novel drug targets and immunotherapies, advances in imaging and biomarkers, clinical trials in progress, and updates to clinical management. There were also oral and rapid abstract sessions, as well as a poster symposium. KidneyCan will once again host the next KCRS in Boston from July 17 to 18, 2025. We hope to see you there!
No takes yet. Share an insight, caveat, or question.
Sood et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: